Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215708 | 0.83 | NAPRT (0.47) | NAPRTNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL5213334 | 0.83 | NPC1 (0.48) | NAPRTSMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL28764683 | 0.81 | ADRB2 (0.46) | NAPRTSMN1; SMN2NPC1RAB9APRKCI | |
| SCHEMBL5211758 | 0.79 | NAPRT (0.46) | NAPRTNOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL24061946 | 0.78 | NAPRT (0.46) | NAPRTALDH1A1PRKCI | |
| SCHEMBL5212527 | 0.75 | GABRP (0.46) | NAPRTNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL12200613 | 0.74 | NAPRT (0.57) | NAPRTNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL7654215 | 0.74 | NAPRT (0.61) | NAPRTNOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL14620960 | 0.72 | NAPRT (0.50) | NAPRTNOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL15607642 | 0.71 | NAPRT (0.57) | NAPRTNOS3NOS1NOS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | NAPRT 1023/4885NOS3 2222/4885NOS1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.